466 related articles for article (PubMed ID: 27376699)
21. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
[TBL] [Abstract][Full Text] [Related]
22. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
Brath H; Bialek C; Gingl E; Resl M; Prager R; Ratzinger M
Wien Klin Wochenschr; 2015 Apr; 127(7-8):250-5. PubMed ID: 25576329
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
Rosales R; Abou Jaoude E; Al-Arouj M; Fawwad A; Orabi A; Shah P; DiTommaso S; Vaz J; Latif ZA
Diabetes Obes Metab; 2015 Jun; 17(6):603-607. PubMed ID: 25586779
[TBL] [Abstract][Full Text] [Related]
27. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
28. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
29. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
[TBL] [Abstract][Full Text] [Related]
30. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
Berndt-Zipfel C; Michelson G; Dworak M; Mitry M; Löffler A; Pfützner A; Forst T
Cardiovasc Diabetol; 2013 Apr; 12():59. PubMed ID: 23565740
[TBL] [Abstract][Full Text] [Related]
31. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
32. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Foley JE; Bhosekar V; Kawamori R
Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
[TBL] [Abstract][Full Text] [Related]
33. [Effectivity and security of vildagliptin as additional treatment for Type 2 diabetes mellitus in real-life conditions in Mexico. EDGE Study subanalysis].
Márquez-Rodríguez E; Brea-Andrea E; Rajmet-Hace VA; Salinas-Salinas J; Mariño-Rojas F
Gac Med Mex; 2016; 152(4):457-64. PubMed ID: 27595248
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
[TBL] [Abstract][Full Text] [Related]
35. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
36. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study).
Suh S; Song SO; Kim JH; Cho H; Lee WJ; Lee BW
J Diabetes Res; 2017; 2017():5282343. PubMed ID: 29057274
[TBL] [Abstract][Full Text] [Related]
38. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
Kozlovski P; Fonseca M; Mohan V; Lukashevich V; Odawara M; Paldánius PM; Kothny W
Diabetes Obes Metab; 2017 Mar; 19(3):429-435. PubMed ID: 27943546
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
40. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
